What is Claimed is:

1. The use of a peptide in the manufacture of a medicament for the treatment of primary biliary cholangitis (PBC), cholestasis, primary sclerosing cholangitis (PSC), bile acid diarrhea (BAD), pregnancy intrahepatic cholestasis (PIC), inborn errors of bile acid synthesis, bile acid malabsorption, or nonalcoholic steatohepatitis (NASH) in a subject, wherein said peptide comprises:

a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121); and

b) a C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises

(i) a first C-terminal region sequence comprising WGDPIRLRHLYTSG (amino acids 16 to 29 of SEQ ID NO:99 [FGF19]), wherein the W residue corresponds to the first amino acid position of the C-terminal region; and

(ii) a second C-terminal region sequence comprising PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFL PLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSM DPFGLVTGLEAVRSPSFEK (amino acid residues 30 to 194 of SEQ ID NO:99 [FGF19]);

wherein the peptide

(i) binds to fibroblast growth factor receptor 4 (FGFR4) with an affinity equal to or greater than FGF19 binding affinity for FGFR4;

(ii) activates FGFR4 to an extent or amount equal to or greater than FGF19 activates FGFR4;

(iii) has at least one of reduced hepatocellular carcinoma (HCC) formation; greater glucose lowering activity, less lipid increasing activity, less triglyceride activity, less cholesterol activity, less non-HDL activity or less HDL increasing activity, as compared to FGF19, or as compared to an FGF19 variant sequence having any of GQV, GDI, WGPI, WGDPV, WGDI, GDPI, GPI, WGQPI, WGAPI, AGDPI, WADPI, WGDAI, WGDPA, WDPI, WGDI, WGDP or FGDPI substituted for the WGDPI sequence at amino acids 16-20 of FGF19 (SEQ ID NO:99); and/or

(iv) has less lean mass reducing activity as compared to FGF21.

2. The use of claim 1, wherein the second C-terminal region sequence of the peptide comprises from 1 to 5 amino acid substitutions, deletions or insertions.

3. The use of claim 1, wherein the peptide is less than about 250 amino acids in length.

4. The use of claim 1, wherein the N-terminal region comprises amino acid residues VHYG (SEQ ID NO:101), or DSSPLVHYG (SEQ ID NO:103).

5. The use of claim 4, wherein the G corresponds to the last position of the N-terminal region.

6. The use of claim 1, wherein the N-terminal region comprises amino acid residues DSSPLLQ (SEQ ID NO:104), and wherein the Q residue is the last amino acid position of the N-terminal region.

7. The use of claim 5, wherein the N-terminal region further comprises:

RHPIP (SEQ ID NO:106), wherein R is the first amino acid position of the N-terminal region;

HPIP (SEQ ID NO:107), wherein H is the first amino acid position of the N-terminal region;

RPLAF (SEQ ID NO:108), wherein R is the first amino acid position of the N-terminal region;

PLAF (SEQ ID NO:109), wherein P is the first amino acid position of the N-terminal region; or

R, wherein R is the first amino acid position of the N-terminal region.

8. The use of claim 6, wherein the N-terminal region further comprises:

RHPIP (SEQ ID NO:106), wherein R is the first amino acid position of the N-terminal region;

HPIP (SEQ ID NO:107), wherein H is the first amino acid position of the N-terminal region;

RPLAF (SEQ ID NO:108), wherein R is the first amino acid position of the N-terminal region;

PLAF (SEQ ID NO:109), wherein P is the first amino acid position of the N-terminal region; or

R, wherein R is the first amino acid position of the N-terminal region.

9. The use of claim 1, wherein the N-terminal region comprises amino acid residues DSSPLLQFGGQV (SEQ ID NO:105), and wherein the V residue corresponds to the last position of the N-terminal region.

10. The use of claim 1, wherein amino acid residues HPIP (SEQ ID NO:107) are the first 4 amino acid residues of the N-terminal region.

11. The use of claim 1, wherein

the first position of the N-terminal region is a R or M residue;

the first and second positions of the N-terminal region is a MR, RM, RD, DS, MD or MS sequence;

the first through third positions of the N-terminal region is a MDS, RDS, MSD, MSS, or DSS sequence;

the first through fourth positions of the N-terminal region is a RDSS (SEQ ID NO:115) or MDSS (SEQ ID NO:116) sequence;

the first through fifth positions of the N-terminal region is an MRDSS (SEQ ID NO:117) sequence;

the first through sixth positions of the N-terminal region is an MDSSPL (SEQ ID NO:119) sequence; or

the first through seventh positions of the N-terminal region is an MSDSSPL (SEQ ID NO:120) sequence.

12. The use of claim 1, wherein the peptide comprises an N-terminus region and a first C-terminal region having an amino acid sequence comprising or consisting of any of:

RPLAFSDSSPLVHYGWGDPIRLRHLYTSG (amino acids 1-29 of SEQ ID NO:2);

PLAFSDSSPLVHYGWGDPIRLRHLYTSG (amino acids 2-29 of SEQ ID NO:2);

RHPIPDSSPLLQWGDPIRLRHLYTSG (amino acids 1-26 of SEQ ID NO:8);

RHPIPDSSPLLQFGWGDPIRLRHLYTSG (amino acids 1-28 of SEQ ID NO:9);

RPLAFSDSSPLVHWGDPIRLRHLYTSG (amino acids 1-27 of SEQ ID NO:26);

PLAFSDSSPLVHWGDPIRLRHLYTSG (amino acids 2-27 of SEQ ID NO:26);

HPIPDSSPLLQWGDPIRLRHLYTSG (amino acids 1-25 of SEQ ID NO:47);

RDSSPLLQWGDPIRLRHLYTSG (amino acids 1-22 of SEQ ID NO:52);

DSSPLLQWGDPIRLRHLYTSG (amino acids 2-22 of SEQ ID NO:52);

MDSSPLVHYGWGDPIRLRHLYTSG (amino acids 1-24 of SEQ ID NO:53);

RDSSPLVHYGWGDPIRLRHLYTSG (amino acids 1-24 of SEQ ID NO:69);

DSSPLVHYGWGDPIRLRHLYTSG (amino acids 2-24 of SEQ ID NO:69);

MRDSSPLVHYGWGDPIRLRHLYTSG (amino acids 1-25 of SEQ ID NO:70);

DSSPLVHYGWGDPIRLRHLYTSG (amino acids 1-23 of SEQ ID NO:141);

or

HPIPDSSPLLQFGWGDPIRLRHLYTSG (amino acids 1-27 of SEQ ID NO:163).

13. The use of claim 1, wherein the N-terminal region first amino acid position is a methionine (M), arginine (R), serine (S), histidine (H), proline (P), leucine (L) or aspartic acid (D) residue.

14. The use of claim 1, wherein the N-terminal region does not have a methionine (M) or arginine (R) residue at the first amino acid position of the N-terminal region.

15. The use of claim 1, wherein the N-terminal region comprises any one of the following amino acid sequences: MDSSPL (SEQ ID NO:119), MSDSSPL (SEQ ID NO:120), or SDSSPL (SEQ ID NO:112).

16. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NOs:2, 8, 9, 26, 52 or 69, wherein the arginine (R) residue at the first amino acid position of the N-terminal region of the sequence is deleted.

17. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:2.

18. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:8.

19. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:9.

20. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:26.

21. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:47.

22. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:52.

23. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:53.

24. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:141.

25. The use of claim 1, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:163.

26. The use of claim 1, wherein the second C-terminal region sequence comprises at least one amino acid substitution to the EIRPD sequence of SEQ ID NO:99.

27. The use of claim 26, wherein the at least one amino acid substitution is to the IRP sequence of the EIRPD sequence of SEQ ID NO:99.

28. The use of claim 26, wherein the at least one amino acid substitution is to the RP sequence of the EIRPD sequence of SEQ ID NO:99.

29. The use of claim 28, wherein the RP sequence is substituted with a LE sequence.

30. The use of claim any one of claims 1 to 29, wherein said peptide is fused with an immunoglobulin Fc region.

31. The use of any one of claims 1 to 30, wherein the peptide has at least one of reduced HCC formation; greater glucose lowering activity, or less lipid increasing activity as compared to FGF19, or as compared to an FGF19 variant having any of GQV, GDI, WGPI, WGDPV, WGDI, GDPI, GPI, WGQPI, WGAPI, AGDPI, WADPI, WGDAI, WGDPA, WDPI, WGDI, WGDP or FGDPI substituted for the WGDPI sequence at amino acids 16-20 of FGF19 (SEQ ID NO:99).

32. The use of claim 31, wherein the HCC formation, glucose lowering activity, or lipid increasing activity is ascertained in a *db/db* mouse.

33. The use of claim 31, wherein the peptide has less lean mass reducing activity as compared to the lean mass reducing activity of FGF21.

34. The use of claim 33, wherein the lean mass reducing activity is ascertained in a *db/db* mouse.

35. The use of any one of claims 1 to 34, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

36. The use of any one of claims 1 to 35, wherein the medicament is prepared for administration to said subject in combination with a supplemental therapy.

37. The use of any one of claims 1 to 36, wherein the medicament modulates bile acid homeostasis in the subject.

38. The use of any one of claims 1 to 36, wherein the medicament reduces CYP7a1 level in the subject.

39. The use of any one of claims 1 to 38, wherein the subject has PBC.

40. The use of any one of claims 1 to 38, wherein the subject has cholestasis.

41. The use of any one of claims 1 to 39, wherein the subject has primary sclerosing cholangitis.

42. The use of any one of claims 1 to 38, wherein the subject has BAD.

43. The use of any one of claims 1 to 38, wherein the subject has PIC.

44. The use of any one of claims 1 to 38, wherein the subject has inborn errors of bile acid synthesis.

45. The use of any one of claims 1 to 38, wherein the subject has bile acid malabsorption.

46. The use of any one of claims 1 to 38, wherein the subject has NASH.

47. The use of a peptide in the manufacture of a medicament for the treatment of PBC, cholestasis, PSC, BAD, PIC, inborn errors of bile acid synthesis, bile acid

malabsorption or NASH in a subject, wherein said peptide has an amino acid sequence comprising or consisting of MRDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQS AHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMV PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:70).

48. The use of claim 47, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70.

49. The use of claim 47, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

50. The use of claim 47, wherein the amino acid sequence comprises at least one amino acid substitution to the EIRPD sequence of SEQ ID NO:70.

51. The use of claim 50, wherein the at least one amino acid substitution is to the IRP sequence of the EIRPD sequence of SEQ ID NO:70.

52. The use of claim 50, wherein the at least one amino acid substitution is to the RP sequence of the EIRPD sequence of SEQ ID NO:70.

53. The use of claim 52, wherein the RP sequence is substituted with a LE sequence.

54. The use of any one of claims 47 to 53, wherein said peptide is fused with an immunoglobulin Fc region.

55. The use of any one of claims 47 to 54, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

56. The use of any one of claims 47 to 52, wherein the medicament is prepared for administration to said subject in combination with a supplemental therapy.

57. The use of any one of claims 47 to 56, wherein the medicament modulates bile acid homeostasis in the subject.

58. The use of any one of claims 47 to 56, wherein the medicament reduces CYP7a1 level in the subject.

59. The use of any one of claims 47 to 58, wherein the subject has PBC.

60. The use of any one of claims 47 to 58, wherein the subject has cholestasis.

61. The use of any one of claims 47 to 58, wherein the subject has primary sclerosing cholangitis.

62. The use of any one of claims 47 to 58, wherein the subject has BAD.

63. The use of any one of claims 47 to 58, wherein the subject has PIC.

64. The use of any one of claims 47 to 58, wherein the subject has inborn errors of bile acid synthesis.

65. The use of any one of claims 47 to 58, wherein the subject has bile acid malabsorption.

66. The use of any one of claims 47 to 58, wherein the subject has NASH.

67. The use of a peptide in the manufacture of a medicament for the treatment of PBC, cholestasis, PSC, BAD, PIC, inborn errors of bile acid synthesis, bile acid malabsorption or NASH in a subject, wherein said peptide has an amino acid sequence comprising or consisting of RDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVP EEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:69).

68. The use of claim 67, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69.

69. The use of claim 67, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

70. The use of claim 67, wherein the amino acid sequence comprises at least one amino acid substitution to the EIRPD sequence of SEQ ID NO:69.

71. The use of claim 70, wherein the at least one amino acid substitution is to the IRP sequence of the EIRPD sequence of SEQ ID NO:69.

72. The use of claim 70, wherein the at least one amino acid substitution is to the RP sequence of the EIRPD sequence of SEQ ID NO:69.

73. The use of claim 72, wherein the RP sequence is substituted with a LE sequence.

74. The use of any one of claims 67 to 73, wherein said peptide is fused with an immunoglobulin Fc region.

75. The use of any one of claims 67 to 74, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

76. The use of any one of claims 67 to 75, wherein the medicament is prepared for administration to said subject in combination with a supplemental therapy.

77. The use of any one of claims 67 to 76, wherein the medicament modulates bile acid homeostasis in the subject.

78. The use of any one of claims 67 to 76, wherein the medicament reduces CYP7a1 level in the subject.

79. The use of any one of claims 67 to 78, wherein the subject has PBC.

80. The use of any one of claims 67 to 78, wherein the subject has cholestasis.

81. The use of any one of claims 67 to 78, wherein the subject has primary sclerosing cholangitis.

82. The use of any one of claims 67 to 78, wherein the subject has BAD.

83. The use of any one of claims 67 to 78, wherein the subject has PIC.

84. The use of any one of claims 67 to 78, wherein the subject has inborn errors of bile acid synthesis.

85. The use of any one of claims 67 to 78, wherein the subject has bile acid malabsorption.

86. The use of any one of claims 67 to 78, wherein the subject has NASH.